Glucarpidase

羧肽酶

Report date: 2022/01/21 09:17:26
First In Class

Base Information

Drug NameGlucarpidase
Drug Alias Name谷卡匹酶glucarpidasaglucarpidaseglucarpidasumCarboxypeptidase G2 +[9] 
ClassificationBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme
Mechanisms of ActionMethotrexate metabolizersGlutamate carboxypeptidase II replacements
TargetsMethotrexate
Therapy Area/IndicationsSolid tumoursCentral Nervous System LymphomaMetabolic Side Effects of Drugs and Substances +[8] 
Global Approved IndicationsMetabolic Side Effects of Drugs and SubstancesDrug-Related Side Effects and Adverse Reactions
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2012/01/17
Country/TerritoryUnited StatesGermanyEU +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesHealth Protection Agency Porton Down
China Registration ClassN/A

Develop Information

Active CompaniesSerb SasOhsu Knight Cancer InstituteCharite University, Berlin, Germany +[5] 
Inactive CompaniesThe University Of Texas MD Anderson Cancer Center
Active IndicationsCentral Nervous System LymphomaMetabolic Side Effects of Drugs and SubstancesDrug-Related Side Effects and Adverse Reactions +[4] 
Inactive IndicationsSolid tumoursHematologic NeoplasmsLymphoma +[4] 

Other Information

ATC CodeV03AF09
Related LinksWikipediaDrugBankKEGG